![]() ![]() 2019 133:530–539 NCT02946463) were stratified by concomitant IST use during the primary evaluation period and extension period of this phase 3, multicenter, randomized, active-controlled, open-label, multicenter study. ![]() Methods: Patient data from Study 301 (Lee JW, et al. However, there are little available data in patients with PNH who may require concomitant ravulizumab and IST.Īims: To evaluate the efficacy and safety of concomitant ravulizumab and IST use in patients with PNH who received ravulizumab up to 52 weeks and those who switched to ravulizumab following the 26 weeks of treatment with eculizumab during the primary evaluation period, and to assess the transfusion requirements in these patients. Previous research has shown that IST is effective when used concomitantly with eculizumab, regardless of the sequence of treatment initiation with IST or eculizumab. Aplastic anemia is a closely related rare bone marrow disorder and commonly treated with immunosuppressive therapy (IST), such as cyclosporine and anti-thymocyte globulin. Botkin Hospital, Moscow, Russian FederationĥLeeds Teaching Hospitals, Leeds, United KingdomĦLaboratory of Cancer Genetics and Gene Transfer, Core Research Laboratory - Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, ItalyħAlexion Pharmaceuticals Inc., Cheshire, CTĨDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, JapanĩHematology Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysiaġ0Hematology Transplant Unit, Hôpital Saint-Louis, Paris, Franceġ1King’s College Hospital NHS Foundation Trust, King’s College, London, UK, and NIHR Wellcome King’s Clinical Research Facility, London, United Kingdomīackground: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disease characterized by uncontrolled complement activation on the surface of PNH blood cells, which can lead to hemolytic anemia. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)ģAlexion Pharmaceuticals, Inc., Boston, MAĤOutpatient Department for Hematology, Oncology and Chemotherapy, S. 2, Anita Hill 3 *, Vadim V Ptushkin 4 *, Viviani Pessoa 5 *, Rosario Notaro 6 *, Jimmy Wang 3 *, Masayo Ogawa, MD, FAAP 7 *, Shinichiro Okamoto, MD, PhD 8 *, Lily LL Wong, MD, FRCPath 9 *, Regis Peffault De Latour, MD, PhD 10 * and Austin G Kulasekararaj, MD, MBBS, MRCP, FRCPath 11ġInstitute of Transfusion Medicine, University of Ulm, Ulm, Germany, and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, GermanyĢSeoul St. Hubert Schrezenmeier 1, Jong Wook Lee, M.D., Ph.D. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |